Skip to main content
REGENERON PHARMACEUTICALS, INC. logo

REGENERON PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · REGN ISIN · US75886F1075 LEI · 549300RCBFWIRX3HYQ56 US Manufacturing
Open in API
Filings indexed 1,720 across all filing types
Latest filing 2026-05-08 Regulatory Filings
Country US United States of America
Listing US REGN

About REGENERON PHARMACEUTICALS, INC.

https://www.regeneron.com/

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. The company's research and development efforts are focused on a wide range of therapeutic areas, including ophthalmology, cancer, allergic and inflammatory diseases, cardiovascular and metabolic disorders, and rare diseases. Regeneron leverages its expertise in biologics and genetic medicines to translate scientific breakthroughs into transformative treatments for patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2026
Regulatory Filings
2026-05-08 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-04-30 English
10-Q - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
Interim / Quarterly Report Q1 2026
2026-04-29 English
8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 29, 2026, reporting the issuance of a press release announcing financial and operating results for the quarter ended March 31, 2026. The text explicitly states that the press release is furnished as Exhibit 99.1 and is incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather serves as a current report to announce the earnings release. According to the rules, such a document is classified as an Earnings Release (ER) because it is the initial announcement of quarterly financial results, typically via a press release, and not a full interim or annual report. The document length is 3603 characters, which is consistent with a short announcement rather than a full report. Therefore, the appropriate classification is ER with high confidence.
2026-04-29 English
ARS
Annual Report
2026-04-24 English
DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS
Proxy Solicitation & Information Statement
2026-04-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.